Actively Recruiting
Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body
Led by National Heart Centre Singapore · Updated on 2024-12-06
200
Participants Needed
1
Research Sites
188 weeks
Total Duration
On this page
Sponsors
N
National Heart Centre Singapore
Lead Sponsor
N
National Medical Research Council (NMRC), Singapore
Collaborating Sponsor
AI-Summary
What this Trial Is About
Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.
CONDITIONS
Official Title
Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 21 years and above
- Healthy volunteers must have no significant medical co-morbidities such as chronic kidney disease, diabetes mellitus, heart failure, ischemic heart disease, or previous strokes
- Healthy volunteers must have no history of cancer
- Patients must have physician-diagnosed cardiovascular conditions such as ischemic heart disease, inherited cardiomyopathies (hypertrophic, dilated or infiltrative), or stable heart failure
- Patients may have cardiometabolic conditions like diabetes requiring medication, hypertension, central obesity, or fatty liver disease
- All participants must be able and willing to comply with study procedures and provide signed informed consent
You will not qualify if you...
- Standard contraindications for magnetic resonance procedures such as implantable medical devices, suspected surgical apparatus or shrapnel, or severe claustrophobia
- Unstable medical conditions including symptomatic heart failure, unstable hypertension or glucose levels, symptomatic arrhythmias, or angina
- Pregnant or nursing women
- Known allergies to pyruvate or any of its components
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Heart Centre Singapore
Singapore, Singapore, 169609
Actively Recruiting
Research Team
C
Calvin WL Chin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here